Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...

The following is a summary of “Neuroretinal and RPE changes and susceptibility to Age-Related Macular Degeneration: insights ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

ONS-5010 is an investigational ophthalmic formulation of bevacizumab, a vascular endothelial growth factor inhibitor, under development as an intravitreal injection.

Lutein plays a pivotal role in safeguarding the eyes by filtering blue light, which can penetrate deep into the eye and ...

As we start the new year, many of us are focusing on diet, exercise, healthy living and our general wellbeing. But did you ...

One habit that can have a detrimental effect on your eyesight is smoking, as it can lead to vision loss and blindness.

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...